Specialty Injectable Generics Market To Witness Growth Owing To Enhanced Usage For Elderly And Action Barrier Patients Till 2026
Specialty injectable is a high cost drug therapy that requires administration by injection, inhalation or infusion. This medication is indicated in treatment of chronic or life threatening diseases such as HIV, rheumatoid arthritis, hemophilia, cancer, cardiovascular diseases, infectious diseases, auto immune disorders, and other diseases.
Request a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1877
Increasing prevalence of chronic diseases such as cancer and cardiovascular diseases is a major factor driving the specialty injectable generics market growth. According to The National Cancer Institute, 2013, there are over 100 different types of cancers that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Moreover, expiration of the patents of majority of pharmaceutical and biotech products in the near future, especially in high value U.S. and Europe market is boosting the market growth.
However, stringent regulatory guidelines and low profit margins and drug shortage is expected to hamper growth of the global specialty injectable generics market. The shortages faced in the industry are primarily due to increased manufacturing issues, delay in supply, and shortage of Active Pharmaceutical Ingredients (API).
Increasing incidences of chronic diseases is expected to propel growth of the global specialty injectable generics market
Specialty injectable generics are used in treatment of complex disease condition such as cancer, hemophilia, HIV, Central Nervous System (CNS)-associated disorders, and others. High prevalence of cancer is expected to drive the market growth. According to World Health Organization (WHO), in 2012, cancer was the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. In 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to increase by around 70% by 2030.
Furthermore, increasing incidences of HIV/AIDS is propelling growth of the specialty injectable generics market over the forecast period. According to WHO, around 36.9 billion people were diagnosed with HIV in 2017, with nearly 1 in every 25 adults in Africa living with HIV. However, expensive and complex process to manufacture the biologics and generic injectables. Not all manufacturers can invest and sustain such investment especially in the ever increasing competition in the specialty injectables generics market.
Major players operating in the global specialty injectable generics market include, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited , Sun Pharmaceutical Industries Limited, and Dr. Reddy’s Laboratories.
Purchase This Premium Report : https://www.coherentmarketinsights.com/insight/buy-now/1877
- Global Specialty Injectable Generics Market, By Product Type:
- Global Specialty Injectable Generics Market, By Application:
- Cardiovascular Diseases
- Central Nervous System Diseases
- Infectious Diseases
- Auto-immune Disorders
- Global Specialty Injectable Generics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Increasing prevalence of neurological disorders in North America is expected to bolster the market growth
North America holds dominant position in the specialty injectable generics market, owing to high prevalence of genetic disorders. According to the U.S. Pharmacist Journal, January 2018, around 1.2 million adults are diagnosed with early symptoms of brain disorders, annually, of which 21% are due to Alzheimer’s disease and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in the U.S.
Moreover, North America is the largest generics drug and biosimilar market worldwide especially in segments of specialty disease and large annual generic/biosimilar prescription. According to report by the U.S. Department of Commerce’s International Trade Administration in 2016, U.S. generic drug sales reached an estimated US$ 70 billion, which is a quarter of the global market. This was due to a large number of drugs going off-patent and healthcare reforms favoring generics. Generics holds 22% of total prescription sales and its share in filled prescriptions increased from 19% in 1984 to 88% in 2015.